Diaceutics PLC Capital Markets Webinar
05 Noviembre 2024 - 1:00AM
RNS Regulatory News
RNS Number : 7065K
Diaceutics PLC
05 November 2024
Diaceutics - PMx Capital
Markets Webinar - Wednesday, 4 December 2024
Belfast and London, 5 November 2024 - Diaceutics PLC
(AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry,
will host a virtual Capital Markets Event for
analysts and investors to discuss PMx - a suite of data and
knowledge driven services built to revolutionise the
commercialisation of precision medicines by removing barriers to
access and adoption, on Wednesday,
4 December 2024 at 1400-1530 GMT (0900-1030 ET).
The event will include presentations
from senior Diaceutics managers and external PMx partners. The
purpose of the event will be to give analysts and investors a
deeper insight into the DXRX platform and Diaceutics recently
launched PMx service which enables Diaceutics' customers to unlock
more value from their product commercialisation and also allows
Diaceutics a greater share and participation in this value
creation.
To register your interest in
attending, please use the following link:
https://us06web.zoom.us/webinar/register/WN_aIuutKaZQrSEYpRDVdr7bg
Enquiries:
Diaceutics
PLC
|
|
Ryan Keeling, Chief Executive
Officer
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
|
|
|
Canaccord
Genuity Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7523 8000
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
About Diaceutics
At Diaceutics we
believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact
their disease outcome. We provide the world's leading pharma and
biotech companies with an end-to-end commercialisation solution for
precision medicines through data analytics, scientific and advisory
services enabled by our platform DXRX - The Diagnostics
Network®.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCDZMGMNMLGDZM
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024